Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.320
+0.050 (3.94%)
At close: Jan 21, 2025, 4:00 PM
1.330
+0.010 (0.76%)
After-hours: Jan 21, 2025, 6:20 PM EST
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2023. The number of employees decreased by 370 or -67.15% compared to the previous year.
Employees
181
Change (1Y)
-370
Growth (1Y)
-67.15%
Revenue / Employee
$74,293
Profits / Employee
-$984,702
Market Cap
150.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
FATE News
- 18 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - GlobeNewsWire
- 7 weeks ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Fate Therapeutics Announces Leadership Transition - GlobeNewsWire
- 2 months ago - Fate Therapeutics to Present at Upcoming December Investor Conferences - GlobeNewsWire
- 2 months ago - Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
- 2 months ago - Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewsWire
- 2 months ago - Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire